HomeAbout usTechnologyBusinessCareersContactEventsDirections
Graffinity - fragment screening
  Graffinity - fragment based drug discovery
GraffinityGraffinity is the premier partner for fragment based drug discovery and lead development of small molecule pharmaceuticals. Graffinity has built a unique approach which includes chemical microarrays, fragment screening, SPR label-free imaging of protein-ligand interactions, computational chemistry and lead discovery. The technology platform offers a new drug discovery paradigm for the rapid conversion of genomic information into novel, high quality leads and drug candidates.
Graffinity applies this technology in established high-profile collaborations with leading Pharma and Biotech companies.

Graffinity - A member of the NovAliX group

Logo Novalix

External Link
  Search using keywords  
  Print this page Print
Latest News
Press Releases:
November 18, 2013:
The NovAliX/KYOWA HAKKO KIRIN Alliance will commence a fragment-based drug discovery Project targeting an important Protein/Protein interaction
External Link read more ...
January 14, 2013:
NovAliX enters into fragment-based drug discovery alliance with KYOWA HAKKO KIRIN
External Link read more ...
External LinkArchive Press Releases
  Printer Print this page
Home | About Us | Technology | Business | Careers | Contact | Events | Directions
Site Information |01.25.2015| Visits:112683 | Today:41| User online:1
© 2004-2015Graffinity
All rights reserved. | Top of page